PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.2122
https://www.valueinhealthjournal.com/article/S1098-3015(12)03836-3/fulltext
Title :
PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03836-3&doi=10.1016/j.jval.2012.08.2122
First page :
A424
Section Title :
Cancer
Open access? :
No
Section Order :
777